Pfizer Corporation

Viiv Healthcare UK Limited

Florian Michel Wakenhut

Gavin Alistair Whitlock

Christoph Martin Dehnhardt

Peter M Jones

Jotham Wadsworth Coe

Karl Richard Gibson

Joseph Walter Strohbach

Andrew Simon Bell

Alan Stobie

Paul Vincent Fish

Yogesh Anil Sabnis

Yogesh Sabnis

David Cameron Pryde

Iain Brian Gardner

Alan Daniel Brown

Michael J Fray

Mark David Andrews

Thomas Ryckmans

Mark Ian Lansdell

Steven Wade Kortum

Martin Peter Green

Toby James Underwood

Steven Wade Korturn

Malcolm Christian Mackenny

A compound having the structure: or a pharmaceutically acceptable salt or solvate thereof, wherein A and A' are C or N, where C may be substituted by halo or C-Calkyl; R and Rare selected from the group consisting of H, C-Calkyl, &#x2014;(CH)&#x2014;W, etc., where W is 5- or 6-membered heteroaryl or heterocyclic containing N, S and/or O atoms, &#x2014;NR&#x2033;SO&#x2014;R&#x2032;, etc., where R&#x2032; and R&#x2033; are C-Calkyl, etc.; wherein each alkyl, etc., may be substituted; or, R and Ro and the N atom to which they are bonded together to form a monocyclic or bicyclic heterocyclic ring, etc.; Ris H, halo or cyano; Rand Rare H, C-Calkyl, etc.; X is a bond, etc.; Ris H, C-Calkyl, etc.; Y is a bond, &#x2014;(CH)&#x2014;, etc. The invention also relates to compositions and uses in the treatment of various diseases.

Pyrazolopyridines and pyrazolopyrimidines

A compound having the structure: or a pharmaceutically acceptable salt or solvate thereof, wherein A and A' are C or N, where C may be substituted by halo or C-Calkyl; R and Rare selected from the group consisting of H, C-Calkyl, &#x2014;(CH)&#x2014;W, etc., where W is 5- or 6-membered heteroaryl or heterocyclic containing N, S and/or O atoms, &#x2014;NR&#x2033;SO&#x2014;R&#x2032;, etc., where R&#x2032; and R&#x2033; are C-Calkyl, etc.; wherein each alkyl, etc., may be substituted; or, R and Rand the N atom to which they are bonded together to form a monocyclic or bicyclic heterocyclic ring, etc.; Ris H, halo or cyano; Rand Rare H, C-Calkyl, etc.; X is a bond, etc.; Ris H, C-Calkyl, etc.; Y is a bond, &#x2014;(CH)&#x2014;, etc. The invention also relates to compositions and uses in the treatment of various diseases.

The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.

Inhibitors of HIV replication

A method of treating a disease or condition for which a JAK inhibitor is indicated in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, and particularly, a method for the treatment of various inflammatory diseases, particularly psoriasis, asthma and COPD.

Indazoles

The present invention relates to compounds of formula (I): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.

A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein,

Amide compounds useful in therapy

A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein Ris H, Calkyl, &#x2014;C(X)Y, Ccycloalkyl, aryl, het, aryl-Calkyl or het-Calkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from Calkyl, Calkoxy, OH, halo, CF, OCF, SCF, hydroxy-Calkyl, Calkoxy-Calkyl and Calkyl-S&#x2014;Calkyl; Ris aryl or heteroaryl, each optionally substituted by at least one substituent independently selected from Calkyl, Calkoxy, OH, halo, CF, OCF, SCF, hydroxy-Calkyl, Calkoxy-Calkyl and Calkyl-S&#x2014;Calkyl; Ris Calkyl, Ccycloalkyl, Ccycloalkyl-Calkyl, aryl, het, aryl-Calkyl or het-Calkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from Calkyl, Calkoxy, OH, halo, CF, OCF, SCF, hydroxy-Calkyl, Calkoxy &#x2014;Calkyl and Calkyl-S&#x2014;Calkyl; X is S or O; Y is H, Calkyl, aryl, het, aryl-Calkyl or het-Calkyl; and n is 1 or 2, provided that when n is 1, m is 0 or 1 and when n is 2, m is 0, wherein if m is 0, then * represents a chiral center. The compounds of the invention exhibit activity as both serotonin and noradrenaline re-uptake inhibitors and therefore have utility in a variety of therapeutic areas, for example urinary incontinence.

Compounds

A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein:

Amides useful as monoamine re-uptake inhibitors

Growing community of inventors

Sandwich, United Kingdom

Florian Michel Wakenhut